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circulating catecholamine levels and peroxynitrite formed from interactions between superoxide anion and nitric oxide may all increase oxidative stress. 14 Several studies have evaluated the potential utility of plasma myeloperoxidase, plasma oxidized low-density lipoproteins (oxidized LDL), serum/urinary isoprostane, urinary biopyrrins, uric acid, and markers of nitro-redox imbalances such as S-nitrosohemoglobin, nitric oxide, and nitrite for evaluation of CHF severity and prognosis. 15- 23 An oxidized nucleoside of DNA, 8-hydroxy-2'-deoxyguanosine , is also reported to be a sensitive biomarker for oxidative DNA damage in vivo. [24] [25] [26] It is reported that the production of reactive oxygen species (ROS) results in mitochondrial DNA damage as evaluated with 8-OHdG in mice with failing hearts after myocardial infarction. 27, 28 Furthermore, 8-OHdG can also be detected immunohistochemically in human cardiac tissue in patients with severe dilated cardiomyopathy (DCM). 29 Recently, we reported that 8-OHdG is produced in failing cardiac tissue on the basis of sampling data from the coronary sinus and aortic root. 30 In addition, the urinary excretion of 8-OHdG is significantly correlated with clinical status and cardiac dysfunction in patients with CHF. 30 Thus, urinary (U) 8-OHdG may be a useful cardiac biomarker for evaluating oxidative stress at the cellular level and predicting the outcome of patients with CHF. In the present study, we investigated whether U8-OHdG is a clinically useful biomarker for predicting the morbidity and mortality of patients with CHF compared with plasma BNP -the current gold standard biomarker for heart failure -and other neurohumoral factors. We also examined whether a combination of plasma BNP and U8-OHdG can reliably be used to stratify the risk of CHF patients for cardiac events.
Methods

Subjects and Study Protocol
One hundred and eighty-six consecutive patients with left ven- 31 Secondary cardiomyopathy was diagnosed according to clinical history, physical examination, electrocardiogram, echocardiography, and cardiac catheterization including endomyocardial biopsy. OMI was defined as revascularization >3 months previously and no ischemic region in the LV on coronary angiography and/or adenosine-induced myocardial perfusion scintigraphy. All CHF patients were enrolled during steady state within 7 days before discharge. Patients with a smoking habit, acute coronary syndrome, acute myocarditis, severe renal failure, cancer, or inflammatory diseases such as infection or collagen disease were excluded from the study irrespective of CHF severity; this is because oxidative stress has been shown to be increased in these systemic diseases. Heart failure severity was evaluated on New York Heart Association (NYHA) class, echocardiography, and/or cardiac catheterization; moreover, we collected morning urine samples to measure the concentrations of U8-OHdG and U8-isoprostane as oxidative stress markers and collected blood samples from peripheral veins for blood biochemistry and to evaluate BNP, IL-6, Ang II, TNF-α, and high-sensitivity C-reactive protein (hsCRP) levels. Blood was centrifuged at 3,000 rpm for 15 min at 4°C, and the plasma was frozen in aliquots and stored at -80°C until assaying. Morning urine was also frozen in aliquots and stored at -80°C until assaying. The CHF patients were prospectively followed for a median follow-up period of 649 days, with endpoints of cardiac death or hospitalization due to progressive heart failure.
A total of 186 patients received standard medications, including ACEI, β-blockers, digitalis, and diuretics ( Table 1) .
Informed consent was obtained from all patients before participation in the study. The protocol was approved by the Human Investigations Committee of Yamaguchi University Hospital and conformed to the Declaration of Helsinki.
Endpoints and Follow-up
No patients were lost to follow-up (median follow-up, 649±505 days) after discharge. Events were centrally adjudicated using medical records, autopsy reports, and death certificates. The first endpoint was defined as cardiac death from worsening heart failure or sudden cardiac death, and the second endpoint was defined as worsening heart failure requiring readmission. Sudden cardiac death was defined as death without definitive premonitory symptoms or signs and was established by the attending physician.
Comparison of U8-OHdG Levels Before and After Carvedilol Treatment
To investigate whether U8-OHdG is useful for evaluating the effectiveness of β-blocker therapy in patients with CHF, 30 consecutive patients who had received standard medication such as diuretics, ACEI/ARB, or aldosterone antagonists, but who had not received β-blocker medications were selected for the present study. A responder was defined as a patient showing clinical improvement of either ≥10% in LVEF or ≥1 class of NYHA functional classification after treatment with a β-blocker. After treatment with β-blockers (mean follow-up period, 12 months), NYHA class, LVEF on echocardiography, BNP, IL-6, Ang II, TNF-α, hsCRP, and U8-OHdG were reexamined to evaluate their usefulness as oxidative stress biomarkers compared with plasma BNP (the gold standard biomarker of heart failure), and the aforementioned neurohumoral and inflammatory biomarkers.
Measurement of U8-OHdG and Other Neurohumoral and Inflammatory Factors
Serum TNF-α and IL-6 levels were determined using the Quantikine HS (Quantikine HS; R&D Systems, Minneapolis, MN, 
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USA) and CLEIA (Fujirebio, Tokyo, Japan) immunoassays. 32 Plasma Ang II levels were measured using a radioimmunoassay with a specific antibody directed against synthetic Ang II as described previously. 33 U8-OHdG levels were measured using a commercially available ELISA kit (Japan Institute for the Control of Aging, Fukuroi, Japan). U8-isoprostane was also determined using an 8-isoprostane EIA kit (Cayman Chemical, Ann Arbor, MI, USA). Raw data were normalized to the urinary level of creatinine (Cr). Plasma BNP was measured using the Shionoria BNP Kit (Shionogi Pharmaceutical, Osaka, Japan). Echocardiographic evaluation was performed by independent echocardiologists. LVEF and cardiac volumes were measured using the Simpson biplane method.
Statistical Analysis
Descriptive statistics for continuous variables are expressed as mean ± SD. Student's t-test was used to compare continuous variables between genders. The chi-square test was used to compare prevalence or frequencies. Cut-offs were defined by the point of maximum sensitivity + specificity upon receiver operating characteristic (ROC) analysis. Kaplan-Meier analysis was performed on the cumulative rates of cardiac eventfree status in patients with CHF who were divided into 2 groups on the basis of cut-offs for BNP, U8-OHdG, U8-isoprostane, or uric acid. Differences between cardiac event-free curves were analyzed using the log-rank test. To identify independent cardiac event predictors, we initially performed univariate and multivariate analyses with Cox's proportional Event free survival rate Time (days) Figure 2 . Receiver operating characteristic analysis of (A) urinary 8-hydroxy-2'-deoxyguanosine (U8-OHdG) and (B) plasma brain natriuretic peptide (BNP). Kaplan-Meier event-free curves for patients with chronic heart failure divided into 2 groups based on cut-off levels for (C) urinary 8-OHdG and (D) plasma BNP. AUC, area under the curve. Heart Failure and Oxidative Stress hazard model in which we included 16 confounding factors.
To refine the models with fewer parameters, we used the stepdown method. We adopted Cox's proportional hazard models to estimate hazard ratios (HR) and their 95% confidence intervals for each factor and to adjust for the effects of confounding factors. P-values were 2-sided, and P<0.05 was considered significant. Statistical analysis was done using SPSS 16.0J (SPSS Japan, Tokyo, Japan). Table 1 summarizes the baseline characteristics of the patients with and without cardiac events. A total of 186 patients with CHF were enrolled in the present study. During the mean follow-up period of 649 days, 63 patients had cardiac events (13 patients died due to worsening heart failure rather than sudden cardiac death, and 50 patients were admitted to hospital for decompensated heart failure; Figure 1 ). There were no differences with respect to gender, age, body mass index, U8-isoprostane, TNF-α, IL-6, fasting blood sugar, hemoglobin A1c, total cholesterol, triglycerides, LDL cholesterol, total bilirubin, heart rate, LV end-diastolic dimension (LVDD), LV enddiastolic volume index (LVEDVI), or treatment with standard medications other than diuretics between the groups with and without cardiac events. But NYHA class, U8-OHdG, Ang II, plasma BNP, serum Cr, uric acid, and hsCRP were significantly higher and systolic blood pressure (SBP), LVEF, and estimated glomerular filtration rate (eGFR) were significantly lower in the group with cardiac events compared to the group without cardiac events.
Results
Baseline CHF Patient Characteristics
Comparison of U8-OHdG and BNP Levels Between Groups
The levels of both U8-OHdG and BNP were significantly higher in patients with cardiac events than in those without ( Table 1) . After dividing the patients with cardiac events into 2 groups (ie, hospitalization and cardiac death), we compared these groups in terms of plasma BNP and U8-OHdG levels to clarify their clinical implications (Figure 1) . U8-OHdG levels in the cardiac death group were significantly higher than those in the hospitalization group (cardiac death, 19.1±7.4 ng/mg Cr vs. hospitalization, 14.8±6.9 ng/mg Cr, P=0.0346), while there was no significant difference in the plasma BNP levels between the 2 groups (cardiac death, 555.0±404.8 pg/ml vs. hospitalization, 569.8±633.7 pg/ml).
Optimal Cut-off Values for Plasma BNP and U8-OHdG
The optimal cut-off values for BNP and U8-OHdG were set at the point of maximum sensitivity plus specificity on each ROC curve. The cut-off level was 12.4 ng/mg Cr for U8-OHdG with a sensitivity of 64.9% and a specificity of 70.4%, and 207 pg/ml for BNP with a sensitivity of 86.0% and a specificity of 59.2% (Figures 2A,B) .
Univariate and Multivariate Analysis of Cardiac Events
We performed linear univariate and multivariate analyses of cardiac events for 16 variables (age, gender, SBP, heart rate, NYHA, U8-OHdG, U8-isoprostane, BNP, Ang II, IL-6, uric acid, hsCRP, sodium, eGFR, LVEDVI, and LVEF) to identify independent predictors of cardiac events ( Table 2 ). Univariate analysis indicated that SBP, NYHA, U8-OHdG, BNP, uric acid, sodium, eGFR, and LVEF were significant predictors. Multivariate analysis identified high levels of SBP (P<0.0001), plasma BNP (P<0.0001), and U8-OHdG (P<0.0001) as significant independent predictors for cardiac events ( Table 2) .
Kaplan-Meier Analysis for Plasma BNP and U8-OHdG
Kaplan-Meier analysis was performed to evaluate the cumulative rates of cardiac event-free status in patients with CHF who were divided into 2 groups on the basis of cut-offs for BNP or U-8-OHdG. It was found that patients with values above the cut-off level had higher cardiac event rates than Table 1 . † Cox proportional model 2 was developed using the stepwise downward method.
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those below the cut-off (Figures 2C,D) .
Cardiac Event Prediction Stratified by a Combination of BNP and U8-OHdG
Patients were stratified into 4 groups according to combinations of cut-off levels of BNP and U8-OHdG (Table 3 ; Figure 3A ). There were no significant differences in gender among the 4 groups. The HR of patients with high BNP and low U8-OHdG, low BNP and high U8-OHdG, and high BNP and high U8-OHdG were 4.2 (P=0.0101), 4.3 (P=0.0133), and 16.2 (P<0.0001), respectively, compared to those with low BNP and low U8-OHdG ( Figure 3B ). Table 4 lists the characteristics of the 30 patients with CHF divided into responder and non-responder groups to carvedilol therapy. After carvedilol treatment, heart rate, LVDD, LVEDVI, BNP, and U8-OHdG decreased with an improvement in LVEF or NYHA class in the responder group but not in the nonresponder group. In the responders and non-responders, the maximum dosage of carvedilol during the follow-up period was 11.9±7.1 mg/day and 7.4±6.3 mg/day, respectively. In the non-responders, the dose of carvedilol could not be increased due to adverse effects such as hypotension and worsening cardiac function compared to the responders. In the profiles based on the combined cut-off levels for U8-OHdG and BNP, the statuses of most of the responder patients moved to "low U8-OHdG and low BNP" (Figure 4A ) after carvedilol treatment, whereas those of most of the non-responder patients did not ( Figure 4B ).
Effectiveness of Carvedilol in CHF Patients According to U8-OHdG
Discussion
The most important finding of the present study is that U8-OHdG is an oxidative stress biomarker that can be used to predict morbidity and mortality; it improves the prediction of cardiac events in combination with plasma BNP in patients with CHF as supported by the following findings. Based on ROC analysis, the cut-off values for U8-OHdG and BNP were determined to be 12.4 ng/mg Cr and 207 pg/ml, respectively. Kaplan-Meier analysis demonstrated that the high U8-OHdG group had a significantly higher incidence of cardiac events than the low U8-OHdG group, as was the case with BNP. Mul- Data given as mean ± SD or % (n). Abbreviations see in Table 1 . *P<0.05 vs. the group with low U8-OHdG (<12.4 ng/mg Cr) and low BNP (<207 pg/ml); † P<0.05 vs. the group with low U8-OHdG (<12.4 ng/mg Cr) and high BNP (> -207 pg/ml). Heart Failure and Oxidative Stress Data given as mean ± SD or % (n). Abbreviations see in Tables 1,2 . tivariate analysis showed that U8-OHdG and BNP were independent predictors of cardiac events. Patients were stratified into 4 groups on the basis of the cut-off levels for both U8-OHdG and BNP ( Table 3) . Patients exceeding only 1 cut-off level had an HR of 4.2-4.3, while patients exceeding both cutoff levels had an HR of 16.2. Thus, a tandem approach using both BNP and U8-OHdG provides additional risk stratification and a better representation of the status of heart failure by evaluating the aspects of both wall stress and oxidative stress.
U8-OHdG as a Predictor of Cardiac Death in CHF Patients
U8-OHdG levels in the cardiac death group were significantly higher than those in the hospitalization group; meanwhile, there was no difference in plasma BNP levels between the 2 groups (Figure 1) . Moreover, in all patients in the cardiac death group, U8-OHdG levels remained high during the follow-up period (data not shown). Thus, a high U8-OHdG level may be a more accurate predictor of cardiac death than BNP level in patients with CHF.
Clinical Implications
There are several advantages of using U8-OHdG as a biomarker for oxidative stress. First, 8-OHdG is partially produced in the failing myocardium; 27-30 thus, U8-OHdG may closely reflect clinical severity with respect to both symptoms and cardiac dysfunction in CHF. 17 Second, U8-OHdG is predictive of morbidity and mortality in patients with CHF; the HR for cardiac events markedly increased when the cut-off levels for both U8-OHdG and plasma BNP were exceeded.
It is reported that β-blockers and renin-angiotensin-aldosterone blockers both inhibit LV remodeling and improve the prognosis of patients with CHF, partly due to their antioxida- Figure 4 . Levels of brain natriuretic peptide (BNP) and urinary 8-hydroxy-2'-deoxyguanosine (U8-OHdG) before and after carvedilol treatment in patients with chronic heart failure in the (A) responder and (B) non-responder groups. Heart Failure and Oxidative Stress tive stress effects. 34-39 Therefore, the present data demonstrate the possibility of treatment guided by both BNP and U8-OHdG as clinical biomarkers (Table 4, Figure 4 ).
Study Limitations
There were 2 significant limitations of the present study. First, this study was a single-center study; only a small number of subjects were analyzed, and only a small number of cardiac events occurred. A larger study is warranted to confirm the prediction of cardiac events according to U8-OHdG levels in patients with CHF. Second, we observed a consistent change in U8-OHdG levels with respect to the response to carvedilol therapy in 30 CHF patients. We could not clarify, however, whether the antioxidant action was a result of the radical scavenging action of carvedilol or the class effects of β-blockers. Further studies are needed to evaluate the efficacy of other β-blockers such as bisoprolol.
Conclusions
U8-OHdG is a useful oxidative stress biomarker for predicting cardiac events in patients with CHF, and substantially enhances the prediction of cardiac events when used in combination with BNP. Furthermore, U8-OHdG has the potential to be a potent biomarker for evaluating the therapeutic effects of β-blockers.
